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Abstract
Background: Sickle cell disease (SCD) is a class of hemoglobinopathy resulting from a single mutation in the
ß-globin chain inducing the substitution of valine for glutamic acid at the sixth amino acid position which leads to
the production of abnormal haemoglobin (haemoglobin S [HbS]). Studies demonstrated the implication of
oxidative stress in the development of the sickle cell disease.
Methods: The study aim was to determine the level of oxidative stress markers in a group of sickle cell
homozygous patients (SS) in the Yaounde Central Hospital above 15 years of age. Hemolysates obtained from
patients were used to investigate some oxidative stress markers including malondialdehyde (MDA), nitric oxide
(NO), catalase (CAT), superoxide dismutase (SOD), peroxidase, total antioxidant capacity (TAC) and total protein
concentration.
Results: Eighty four individuals, 42 males and 42 females participated (50 % each) with an age range of 15 to
55 years. The levels of markers were significantly higher in the healthy AA group than sickle (SS) (p < 0.05), with the
exception of MDA which was significantly high in sickle cell (SS) patients than healthy (p = 0.037). With respect to
the gender, both healthy and SS females showed a greater Total anti-oxidant capacity (65 μM) compared to the
males (55 μM).
Conclusion: The increase in the oxidative stress level especially MDA in sickle cell homozygous patients compared
to healthy AA individuals confirms that oxidative stress is involved in the pathogenesis of the sickle cell disease.
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Background
Sickle cell disease (SCD) was the first disease to be char-
acterized by a mutation of a gene encoding the human
β-globin subunit with the resulting replacement of β6
glutamic acid by valine [1]. Sickled Hb is associated with
steady state increases in plasma cell-free hemoglobin
and overproduction of reactive oxygen species (ROS).
The generation of reactive oxygen species is a steady-state
cellular event in respiring cells and their production can
be amplified in response to a variety of pathophysiological
conditions such as inflammation, immunologic disorders,
hypoxia [2]. Reactive oxygen species can cause damage to
biological macromolecules such as proteins, lipids and
DNA. Patients with SCD are subjected to increased oxida-
tive stress particularly during vaso-occlusive crises and
acute chest pain [1, 3]. Oxidative stress represents the im-
balance between enhanced generation of reactive oxygen
species and low cellular content of antioxidants. Oxidative
damage has been shown to change a number of RBC
membrane properties, alter membrane permeability and
lead to hemolysis. The major defense systems against ROS
and oxidative stress include those that scavenge free
radicals such as glutathione, vitamin C, vitamin E and
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superoxide dismutase and that reduce hydroperoxides
formed by glutathione peroxidase and catalase.
Sickle-cell anemia has a high prevalence throughout
equatorial Africa; additionally, the genetic defect is now
known to be widespread in parts of Sicily and southern
Italy, northern Greece, southern Turkey, the Middle
East, Saudi Arabia, much of central India, and the Americas
[4]. The prevalence of sickle cell trait in western, central
and eastern Africa varies from 5 to 40 % but it is less
common in northern and southern Africa [5]. Three
quarters of all sickle cell cases occur in Africa and the
total number of carriers in the world is estimated to be
about 120 million. In Cameroon, the prevalence of the
sickle cell trait is estimated to be 18.2 % for the hetero-
zygous form and 2–3 % for the homozygous SS forms
[3]. The prevalence of SCD is increasing and becoming
alarmingly common in the Cameroon. Very few studies
have been carried out on the role of free radicals and
profile of anti-oxidant in this region. Moreover no study
has been conducted to compare pro-oxidant and anti-
oxidant status of homologous patients. It is relevant
therefore to evaluate the oxidative status of homozygous
SS patients and to identify whether these markers could
be associated with the physiopathology of the disease.
Methods
Recruitment of participants
A total of eighty four patients were included (42 sickle cell
patients and a control group of 42 healthy individuals
matched for age and sex with the patients) in the study.
They were all above 15 years of age. The study was carried
out in the Yaounde Central Hospital. Analytical study in-
volved the comparison of two groups. The study took
place from December 2013 to April 2014. The sample size
was calculated using the Formula of Lorentz which takes
into consideration the prevalence of homozygous SS pa-
tients in Cameroon. (2–3 %) [6]. None of the patients or
the controls had a history of concomitant chronic illness
like diabetes, evidence of cardiovascular, hepatic, renal, or
gastrointestinal disease or the presence of chronic infec-
tious illnesses (Rhumatoid athritis, AIDS) and had not re-
ceived a blood transfusion within 3 months of the study.
Information on the study was given to the potential partic-
ipants and their legal guardians (if need be) in their first
official languages. Patients read and signed the informed
consent form. For each participant, demographic data was
obtained and noted unto a pre structured data collection
sheet. The study was approved by the ethical committee
of the Faculty of Medicine and Biomedical Sciences of the
University of Yaounde 1 (Cameroon).
Blood sample collection
Five milliliters of venous blood was collected from each
participant into a tube containing Ethylene Diamine
Tetra Acetate (EDTA). The blood was then centrifuged
at 1000 rpm for 15 min. The plasma and buffy coat were
removed and sickle RBCs were lysed with ice cold water
and the clear lysate obtained after spinning down the
cell debris at 5000 rpm for 10 min at 4 °C was used for
the assays.
Biochemical analyses
The superoxide dismutase (SOD) activity was deter-
mined using the Misra and Fridovich method which is
based on the fact that SOD inhibits the oxidation of
adrenaline to adrenochrome. Adenochrome formed can
be detected in a spectrophotometer at 480 nm by its
pink color [7].
The catalase activity was determined following the
addition of hydrogen peroxidase and dichromate/acetic
acid by the detection of perchromic acid precipitates
whose absorbance was read at 570 nm by spectropho-
tometry [8]. The catalase activity was expressed as mi-
cromoles of H2O2/ min/mg of protein.
Lipid peroxidation assay was performed by a formerly
described protocol [9]. Aldehydes, lipid peroxidation of
products and malondialdehyde (MDA), an end product
of lipid peroxidation of erythrocytes, can react with thio-
barbituric acid (TBA) to form a colored complex called
thiobarbituric acid reactive substance (TBARS), which
was assayed spectrophotometrically at 532 nm and
expressed in micro moles.
The Nitric Oxide (NO) determination was done by
using the Greiss’ reagent. In this experiment, nitrite is
mixed with sulphanilamide and then with N-naphthyl
ethylenediamine. This produces a purple colour and the
concentration of nitric acid can be read at an absorbance
of 540 nm and expressed in micro molar [10].
Peroxidase activity was determined by the peroxidase
kit (CAS Number 7722-84-1, Sigma Aldrich). It as an
enzymatic method using pyrogallol as the substrate to
determine the activity of peroxidase and the absorbance
was read at 420 nm.
The total antioxidant capacity (TAC) of the hemoly-
sate was measured using a Ferric Reducing Antioxidant
Power (FRAP), a method that determined the capacity
of a sample to reduce iron (Fe3+) at the acidic pH (3.6).
An intense blue color is formed when ferric tripyridyl-
triazide (TPTZ-Fe3+) complex is reduced to ferrous





Males SS 26.2 ± 9.0 21.5 ± 3.9
Females SS 24.4 ± 8.6 21.9 ± 3.6
Males control 28.5 ± 8.8 23.4 ± 4.0
Females control 24.4 ± 7.3 25.5 ± 3.3
Ama Moor et al. BMC Clinical Pathology  (2016) 16:15 Page 2 of 5
tripyridyltriazine (TPTZ-Fe-2+) and the absorbance
measured at 593 nm. The result is expressed in micro
molar [11].
Statistical analyses
The results were presented as mean ± standard deviation
using the software Graphpad Insat. The non-parametric
Mann Whitney U test was applied to detect the signifi-
cant difference between the groups. We also used
ANOVA for one way analyses. Non-parametric distribu-
tion was analysed by Kruskal Wallis followed by Dunn’s
multiple Comparison test which is a post – hoc test with
a p- value of < 0.05 considered statistically significant.
Results
Eighty four patients were included in the study among
them 42 sickle cell patients and 42 healthy individuals
matched for age and sex (Table 1). There was an equal
distribution of males and females in each group, giving a
male to female ratio of 1:1. Our target age for sickle pa-
tients was 15 to 55 years old with a mean of 25 ± 8 years.
Concerning our control group, the age range was from
18 to 53 years with a mean age was 26 ± 7 years. There
was a general decrease in the Body Mass Index (BMI) of
sickle cell patients as compared to healthy individuals in
both male and female groups (Table 1). The levels of
SOD, CAT, TAC and NO were significantly (p < 0.05)
higher in the healthy group compared to the sickle cell
group. On the contrary, the concentration of MDA was
significantly higher in the sickle group. There was no
significant difference in the peroxidase activity of both
groups (Table 2). Tables 3 and 4 showed the variation of
oxidative marker with respect of sex for sickle and
healthy patients. The results showed that except for
TAC which was significantly higher in the sickle female
patients group, there was not significant variation in the
markers between males and females. The concentration
of TAC was also significantly higher in females in the
AA controls patients (Table 4).
Discussion
The role of oxidant damage to red cells in sickle cell
anemia has been of interest in recent years. The gener-
ation of reactive oxygen species is a steady-state cellular
event in respiring cells. Their production can be grossly
amplified in response to a variety of pathophysiological
conditions such as inflammation, immunologic disor-
ders, hypoxia, hyperoxia, metabolism of drugs or alco-
hol, exposure to UV or therapeutic radiation, and
deficiency in antioxidants enzymes [12]. SCD is a heredi-
tary disorder with higher potential for oxidative damage
due to chronic redox imbalance in red cells that often
results in clinical manifestation of mild-to severe
hemolysis in patients with this genetic disorder [13]. It
was shown that SS patients produced greater quantities
of O2−, H2O2 and OH
· than AA patients with normal
red blood cells [14]. The present study investigated the
variation between pro and antioxidant markers of the
homozygote sickle and healthy patients and the results
showed that the activities of SOD, CAT, NO and TAC
were significantly decreased in the SS subjects as com-
pared with the control normal subject group AA. The
deficiency of the activities of these enzymes may be at-
tributed to the high production of ROS in these patients
which may destroy these antioxidant enzymes [2]. Some
previous studies demonstrated that the activities of SOD,
CAT and peroxidase were reduced while others reported
that the activities of both SOD and peroxidase were in-
creased [15, 16]. The decrease of the levels of SOD in
the sickle patients as found in this study could be able to
increase the flux of superoxide ion exposing the sickle
erythrocytes to high level of hydrogen peroxide. Further-
more, the increase of MDA in the same group can be at-
tributed to the auto-oxidation of iron seen in these
Table 2 Levels of oxidative markers in sickle and healthy individuals
Catalase (U/mg prot) SOD (U/mg of prot) MDA (μM) Peroxidase (U/mg of prot) NO (μMl) TAC (μM) (MDA*100/TAC)
Healthy AA 795 ± 15 14.9 ± 1.7 0.012 ± 0.002 0.024 ± 0.004 9.8 ± 0.66 0.76 ± 0.07 1.5
Sickle SS 697 ± 20 6.5 ± 1.4 0.018 ± 0.004 0.033 ± 0.006 8.7 ± 0.69 0.68 ± 0.14 2.64
p- value 0.0001** 0.002** 0.037** 0.339 0.04** 0.001**
AA healthy patient without sickle cell disease, SOD super oxide dismutase, MDA malondialdehyde, NO nitrogen oxide, TAC total antioxydant capacity, prot protein
**Statistically significant
Table 3 Variation of stress markers in sickle patients with respect to sex
Catalase (U/mg prot) SOD (U/mg prot) MDA (μM) Peroxidase (U/mg prot) NO (μM) TAC (μM) MDA*100/TAC
SS males 5.2 ± 1.2 0.7 ± 0.15 2.2 ± 0.33 0.03 ± 0.00 8.8 ± 1.5 0.55 ± 0.05 4
SS females 6.5 ± 1.3 0.8 ± 0.11 2.1 ± 0.21 0.05 ± 0.00 8.9 ± 1.8 0.65 ± 0.04 3
p- value 0.85 0.163 0.18 0.267 0.50 0.009**
SOD super oxide dismutase, MDA malondialdehyde, NO nitrogen oxide, TAC total antioxydant capacity, prot protein
**Statistically significant
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patients [15]. Also, the excess production of MDA has
additional toxic effects leading to alterations of the pro-
teins, modifications of amino-acid side chain, and lipids
structure. These alterations may result in a partial or
complete loss of protein functionality including antioxi-
dant enzymes, protein receptors [2, 17] and cause
externalization of phosphatidylserine in red cell mem-
branes which can enhance complement activation and
cell lysis [12].
The data showed that except for MDA, there was an
increase of the remaining oxidative stress markers tested
in both females SS and healthy patients. Difference be-
tween males and females in this study may also be due
to the fact that women have a source of antioxidant pro-
tection (oestrogen) which is low or absent in men [18].
Previous study demonstrated similar results [19]. MDA,
which is major aldehyde product of lipid peroxidation,
reflects damage to lipids. Many studies support the role
of estrogens in the primary and secondary prevention of
Cardiovascular Disease (CVD) among women, particularly
in normalizing blood lipids or inducing endothelium-
dependent vasodilation stimulating nitric oxide synthetase
[20]. The severe alteration of the oxidative pattern in the
male homozygote SS may offer one possible pathogenetic
explanation for the higher incidence of crisis and compli-
cations observed in SS males than females.
Conclusion
These results show a statistically significant increase of
the concentration of MDA and a statistically significant
decrease of catalase, SOD, NO, TAC in sickle cell pa-
tients compared to the healthy controls group. The level
of peroxidase was not different between the two groups.
With respect to the gender, healthy and SS female
groups show a greater level of TAC compared to the
males. In the sickle cell patients, the reduction of anti-
oxidant defense mechanisms can lead to damage of cel-
lular organelles and enzymes and cause an increase of
lipid peroxidation.
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